BASF to strengthen its Pharma Solutions business with Orgamol acquisition
Orgamol is an important player in the contract manufacturing market and supplies exclusive ingredients to customers in the pharmaceutical industry. In 2004, the company posted sales of approximately €100 million.
All Swiss employees at Orgamol have been invited by the foundation to a meeting on June 25, 2005 to vote on the sale of the remaining shares to BASF. The sale must be ratified by two-thirds of the employees present at the meeting.The acquisition of Orgamol would place BASF among the top 10 providers of pharma contract manufacturing solutions in the world. “This is a strategic step on the way to expanding our fine chemicals business further and achieving sales of €3 billion and an EBITDA margin before special items of 20 percent,” said Martin Laudenbach, head of BASF’s Fine Chemicals division. “We will draw in particular on the enormous expertise of Orgamol’s workforce to ensure our future success of our activities in the area of Pharma Solutions,” he continued.
Orgamol is an important player in the contract manufacturing market and supplies exclusive ingredients to customers in the pharmaceutical industry. In 2004, the company posted sales of approximately €100 million. The planned acquisition includes the headquarters of Orgamol in Evionnaz close to Lake Geneva as well as the company’s second production site in Saint-Vulbas near Lyon, France. Orgamol has about 450 employees at its two sites. The company was established in Switzerland in 1952 and has since then been in private ownership.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
